2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1388

Distinct Clinical Correlates of Immune Thrombocytopenic Purpura at Diagnosis of Childhood-Onset and Adult SLE

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1321

Distinguishing Features of Polymicrobial Septic Arthritis

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1745

Disturbance of Renal Circadian Rhythm in Lupus Nephritis

Systemic Lupus Erythematosus – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 1093

DNA Methylation Defines Joint Specific Differences in Synovial Fibroblasts from OA and RA Patients

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1317

Do Patients with MRSA-Positive Septic Arthritis Differ Clinically from Non-MRSA-Positive Counterparts?

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1674

Do TNF Inhibitors Change the Progression of Sacroiliitis?

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

9:00AM-11:00AM: Abstract Number: 1517

Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1251

Does Preconsult Electronic Exchange Affect Postconsult Diagnosis?

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1234

Does SLE Care in a Lupus Clinic Result in Higher Quality Scores Than in General Rheumatology Clinics?

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1694

Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1644

Dose Selection of Filgotinib, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 3 Studies: Exposure-DAS28 and ACR Modeling Approach

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1597

Dose-Response Modeling Is a Useful Tool to Determine Doses for Phase 3: Experience from Olokizumab

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1754

Double-Negative T (DNT) Cell over-Expressing PD-1 and Helios Is Responsible for Lupus Tissue Injury in Systemic Lupus Erythematosus (SLE): Direct Proof That Increased Interferon Alpha (IFNα) Expression Is Sufficient to Induce SLE in Ifnα-Transgenic Mice

Systemic Lupus Erythematosus – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 1750

Down-Regulation of microRNA-200a-3p, Targeting C-Terminal Binding Protein-2 (CtBP2), Is Involved in Hypoproduction of IL-2 in SLE-Derived T Cells

Systemic Lupus Erythematosus – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 1841

Dysregulation of the Splicing Machinery Components in Leukocytes from Patients with Systemic Lupus Erythematosus: Influence on Autoimmune and Atherothrombotic Mechanisms

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].